Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma
<p>Abstract</p> <p>Background</p> <p>To evaluate efficacy and feasibility of chemo-radiotherapy in patients with non-metastatic anal squamous-cell-cancer.</p> <p>Methods</p> <p>TNM staged anal squamous-cell cancer patients were treated with pelvi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-02-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/11/55 |
| _version_ | 1818484973477298176 |
|---|---|
| author | Petralia Giuseppe Fodor Cristiana Petazzi Elena Santoro Luigi Leonardi Maria C Magni Elena Zampino Maria G Trovato Cristina Nolè Franco Orecchia Roberto |
| author_facet | Petralia Giuseppe Fodor Cristiana Petazzi Elena Santoro Luigi Leonardi Maria C Magni Elena Zampino Maria G Trovato Cristina Nolè Franco Orecchia Roberto |
| author_sort | Petralia Giuseppe |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>To evaluate efficacy and feasibility of chemo-radiotherapy in patients with non-metastatic anal squamous-cell-cancer.</p> <p>Methods</p> <p>TNM staged anal squamous-cell cancer patients were treated with pelvic radiotherapy concomitant to continuous infusion fluorouracil plus cisplatin for at least 2 cycles. In T3-T4 or any T - N+ tumours or in "slow-responder" cases, 1-2 chemotherapy courses were subsequently administered. Tumour assessment was performed at baseline and 6-8 weeks after radiotherapy to evaluate response.</p> <p>Results</p> <p>29 patients were enrolled: 4 males, 25 females; median age 57 years; baseline T1/T2/T3/T4 2/12/7/8; N involvement 17. Median dose pelvic radiotherapy was 59.4 Gy (range: 54-74). In 5 patients 2 chemotherapy courses, in 12 patients three and in 12 patients four courses were performed. At first evaluation, 27 CR (93.1%; 95% CI: 78% - 98%) and 2 SD were observed. Main grade (G) 3 toxic events were neutropenia (8%), diarrhoea (8%) and dermatitis (62%). Most frequent late events G3-G4 occurred in 14 patients: proctitis (5), dermatitis (4), bladder dysfunctions (2), sexual dysfunctions (9), lower extremity venous thromboses (2), dysuria (1), stenosis (1) and tenesmus (1). Five patients reported G1 leucopoenia. The rate of colostomy was 14%. After a median follow up of 42 months (range: 4-81), 20 patients are still alive without relapse and 3 died due to PD. The estimated 7-year DFS was 83.4% (C.I.: 68.3%-98.5%) and the estimated 7-year OS was 85.7% (C.I.: 70% - 100%). The 1-year and the estimated 7-year colostomy-free survivals were 85.9% (C.I.: 73.1% - 98.7%).</p> <p>Conclusions</p> <p>Concurrent cisplatin plus fluorouracil and radiotherapy is associated with favourable local control rates and acute toxicity. Future investigations will be directed towards research into molecular biomarkers related to disease progression and resistance to chemo-radiotherapy and to the evaluation of new cytotoxic agents or targeted drugs, such as anti-epidermal growth factor receptor, concomitant to RT and to determining the role of intensity-modulated radiotherapy.</p> |
| first_indexed | 2024-12-10T16:01:55Z |
| format | Article |
| id | doaj.art-6f3f49f59f724e53ba988843510c910e |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-10T16:01:55Z |
| publishDate | 2011-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-6f3f49f59f724e53ba988843510c910e2022-12-22T01:42:24ZengBMCBMC Cancer1471-24072011-02-011115510.1186/1471-2407-11-55Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinomaPetralia GiuseppeFodor CristianaPetazzi ElenaSantoro LuigiLeonardi Maria CMagni ElenaZampino Maria GTrovato CristinaNolè FrancoOrecchia Roberto<p>Abstract</p> <p>Background</p> <p>To evaluate efficacy and feasibility of chemo-radiotherapy in patients with non-metastatic anal squamous-cell-cancer.</p> <p>Methods</p> <p>TNM staged anal squamous-cell cancer patients were treated with pelvic radiotherapy concomitant to continuous infusion fluorouracil plus cisplatin for at least 2 cycles. In T3-T4 or any T - N+ tumours or in "slow-responder" cases, 1-2 chemotherapy courses were subsequently administered. Tumour assessment was performed at baseline and 6-8 weeks after radiotherapy to evaluate response.</p> <p>Results</p> <p>29 patients were enrolled: 4 males, 25 females; median age 57 years; baseline T1/T2/T3/T4 2/12/7/8; N involvement 17. Median dose pelvic radiotherapy was 59.4 Gy (range: 54-74). In 5 patients 2 chemotherapy courses, in 12 patients three and in 12 patients four courses were performed. At first evaluation, 27 CR (93.1%; 95% CI: 78% - 98%) and 2 SD were observed. Main grade (G) 3 toxic events were neutropenia (8%), diarrhoea (8%) and dermatitis (62%). Most frequent late events G3-G4 occurred in 14 patients: proctitis (5), dermatitis (4), bladder dysfunctions (2), sexual dysfunctions (9), lower extremity venous thromboses (2), dysuria (1), stenosis (1) and tenesmus (1). Five patients reported G1 leucopoenia. The rate of colostomy was 14%. After a median follow up of 42 months (range: 4-81), 20 patients are still alive without relapse and 3 died due to PD. The estimated 7-year DFS was 83.4% (C.I.: 68.3%-98.5%) and the estimated 7-year OS was 85.7% (C.I.: 70% - 100%). The 1-year and the estimated 7-year colostomy-free survivals were 85.9% (C.I.: 73.1% - 98.7%).</p> <p>Conclusions</p> <p>Concurrent cisplatin plus fluorouracil and radiotherapy is associated with favourable local control rates and acute toxicity. Future investigations will be directed towards research into molecular biomarkers related to disease progression and resistance to chemo-radiotherapy and to the evaluation of new cytotoxic agents or targeted drugs, such as anti-epidermal growth factor receptor, concomitant to RT and to determining the role of intensity-modulated radiotherapy.</p>http://www.biomedcentral.com/1471-2407/11/55 |
| spellingShingle | Petralia Giuseppe Fodor Cristiana Petazzi Elena Santoro Luigi Leonardi Maria C Magni Elena Zampino Maria G Trovato Cristina Nolè Franco Orecchia Roberto Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma BMC Cancer |
| title | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| title_full | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| title_fullStr | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| title_full_unstemmed | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| title_short | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| title_sort | concurrent cisplatin continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| url | http://www.biomedcentral.com/1471-2407/11/55 |
| work_keys_str_mv | AT petraliagiuseppe concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT fodorcristiana concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT petazzielena concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT santoroluigi concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT leonardimariac concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT magnielena concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT zampinomariag concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT trovatocristina concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT nolefranco concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma AT orecchiaroberto concurrentcisplatincontinuousinfusionfluorouracilandradiotherapyfollowedbytailoredconsolidationtreatmentinnonmetastaticanalsquamouscellcarcinoma |